华东医药股份有限公司 市值管理制度 第一章 总则 第一条 为加强华东医药股份有限公司（以下简称"公司"）市值管理工作， 进一步规范公司的市值管理行为，切实维护公司、投资者及其他利益相关者的合 法权益，根据《中华人民共和国公司法》《中华人民共和国证券法》《国务院关 于加强监管防范风险推动资本市场高质量发展的若干意见》《上市公司信息披露 管理办法》《上市公司监管指引第 10 号——市值管理》等相关法律法规和规范 性文件及《华东医药股份有限公司章程》（以下简称"《公司章程》"）的规定， 并结合公司实际制订本制度。 第二条 本制度所称市值管理，是指公司以提高公司质量为基础，为提升公 司投资价值和股东回报能力而实施的战略管理行为。 第二章 市值管理的目的与基本原则 第三条 市值管理主要目的是通过充分、合规的信息披露，增强公司透明度， 引导公司的市场价值与内在价值趋同，同时通过制定正确发展战略、完善公司治 理、改进经营管理、培育核心竞争力等方式并利用资本运作、投资者关系管理等 手段，使公司价值得以充分实现，建立稳定和优质的投资者基础，获得长期的市 场支持，从而达到公司整体利益最大化和股东财富增长并举的目标。 第四条 公司 ...

华东医药股份有限公司 独立董事高向东 2024 年度述职报告 （二）是否存在影响独立性的情况说明 作为华东医药的独立董事，报告期内，本人不在华东医药担任除 独立董事外的其他职务，与华东医药及其主要股东不存在直接或者间 接利害关系，或者其他可能影响其进行独立客观判断关系；独立履行 职责，不受华东医药及其主要股东等单位或者个人的影响。 各位股东及股东代表： 作为华东医药股份有限公司（以下简称"本公司"或"公司"或"华 东医药"）第十届董事会独立董事，在 2024 年度的工作中，本人严格 按照《中华人民共和国公司法》《中华人民共和国证券法》《上市公 司独立董事管理办法》《深圳证券交易所股票上市规则》等有关法律、 法规及《公司章程》《公司独立董事工作制度》等公司规章制度的相 关规定和要求，本着对公司及全体股东负责的态度，勤勉、忠诚地履 行独立董事的职责和义务，从全体股东利益的角度出发，对公司的发 展和风险控制等重大问题提出有益的意见和建议，积极推动董事会规 范运作和公司治理水平的提升，切实维护公司、全体股东特别是中小 股东的合法权益。现将本人 2024 年度的履职情况汇报如下： 一、独立董事的基本情况 （一）个人基本 ...

一、独立董事的基本情况 （一）个人基本情况 本人王如伟，1967 年出生，日本国立岛根大学医学博士，教授级 高工、博士生导师（浙江大学、沈阳药科大学、浙江中医药大学）。 曾任温州医科大学附属六院业务副院长，浙江康恩贝制药股份有限公 司副董事长、总裁，嘉和生物股份有限公司副董事长、总裁，杭州泰 格医药科技股份有限公司执行副总裁，杭州泰珑创业投资合伙企业 （有限合伙）创始合伙人、董事总经理等职务。2010 年至今任国家药 典委员会委员，2022 年 6 月 1 日至今任本公司独立董事，同时兼任 中科院特聘研究员，现任浙江寿仙谷医药股份有限公司独立董事、扬 华东医药股份有限公司 独立董事王如伟 2024 年度述职报告 各位股东及股东代表： 作为华东医药股份有限公司（以下简称"本公司"或"公司"或 "华东医药"）第十届董事会独立董事，在 2024 年度的工作中，本 人严格按照《中华人民共和国公司法》《中华人民共和国证券法》《上 市公司独立董事管理办法》《深圳证券交易所股票上市规则》等有关 法律、法规及《公司章程》《公司独立董事工作制度》等公司规章制 度的相关规定和要求，本着对公司及全体股东负责的态度，勤勉、忠 诚地履 ...

华东医药股份有限公司 舆情管理制度 第一章 总则 第一条 为提升华东医药股份有限公司（以下简称 "公司"）应对各类舆情 的能力，建立快速反应和应急处置机制，正确把握和引导网络舆论导向，及时、 妥善处理各类舆情对公司股价、公司商业信誉及正常生产经营活动造成的影响， 切实维护公司、投资者及其他利益相关者的合法权益，根据《中华人民共和国公 司法》《中华人民共和国证券法》《上市公司监管指引第 10 号——市值管理》 《深圳证券交易所股票上市规则》《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》等相关法律法规和规范性文件及《华东医药股份 有限公司章程》（以下简称"《公司章程》"）的规定，并结合公司实际制订本 制度。 第二条 本制度所称"舆情"包括： （一）报刊、电视、网络等媒体对公司进行的负面报道； （二）社会上存在的已经或将给公司造成不良影响的传言或信息； （三）可能或者已经影响社会公众投资者投资取向，造成股价异常波动的信 息； （四）其他涉及公司信息披露且可能对公司股票及其衍生品交易价格产生较 大影响的事件信息。 第三条 舆情信息的分类： （一）重大舆情：指传播范围较广，严重影响公司公众形象 ...

Financial Performance - In 2024, the company achieved a revenue growth of 21.24% and a net profit growth of 52.59% compared to 2021, reaching historical highs[4] - Huadong Medicine reported a revenue of CNY 1.2 billion for Q3 2023, representing a year-over-year increase of 15%[22] - The company achieved a net profit of CNY 300 million in Q3 2023, up 20% compared to the same period last year[22] - The company's operating revenue for 2024 reached ¥41.91 billion, an increase of 3.16% compared to ¥40.62 billion in 2023[36] - Net profit attributable to shareholders for 2024 was ¥3.51 billion, representing a growth of 23.72% from ¥2.84 billion in 2023[36] - The basic earnings per share for 2024 was ¥2.0046, up 23.60% from ¥1.6219 in 2023[36] - The company reported a gross margin of 45% for Q3 2023, maintaining a stable margin compared to the previous quarter[22] - The company has set a performance guidance of CNY 5 billion in total revenue for the fiscal year 2024, reflecting a growth target of 20%[22] - The company’s net asset return (ROE) stood at 15.93%[60] - The company’s gross profit margin improved to 33.21%, an increase of 0.81 percentage points year-on-year[60] Product Development and Innovation - The company launched several innovative products, including the first domestic ADC drug for platinum-resistant ovarian cancer and the first biosimilar of ustekinumab in China[4] - The innovative drug pipeline has surpassed 80 projects, with ongoing clinical development for GLP-1 receptor agonists and FDA orphan drug designation for self-developed ADC drugs[5] - The company is investing CNY 200 million in R&D for new drug development, focusing on GLP-1 analogs[22] - The company has developed over 80 innovative drug pipelines, ranking among the top tier in the domestic pharmaceutical industry, focusing on oncology, endocrinology, and autoimmune diseases[45] - The company has a comprehensive product line in diabetes treatment, with over 20 commercialized and in-development products targeting mainstream clinical treatment points[47] - The company has a strong focus on innovative drug development in the fields of chronic kidney disease, immune disorders, and oncology, with a differentiated product matrix including ADCs and GLP-1 receptor agonists[46] - The company has over 20 innovative biological and small molecule products in the autoimmune disease field, with several applications approved in late 2024 and early 2025 for various indications[117] - The company’s first ADC new drug, IMGN853, received conditional approval from NMPA in November 2024 for treating platinum-resistant ovarian cancer[106] - The company’s first self-developed ADC project, HDM2005, has completed the first patient enrollment in the Phase I clinical trial in August 2024[108] Market Expansion and Strategy - Huadong Medicine plans to expand its market presence in Southeast Asia, targeting a 30% increase in market share by 2025[22] - The company is actively expanding its international market presence, focusing on integrating into the global pharmaceutical supply chain[81] - The company aims to enhance its R&D capabilities and accelerate the launch of new products, focusing on oncology, endocrine, and autoimmune diseases, with a commitment to increasing R&D investment[188] - The company is committed to establishing a global operational layout for its medical aesthetics business, leveraging high-quality international products to penetrate the Chinese market[186] - The company plans to enhance its product pipeline depth and breadth in the medical aesthetics sector, ensuring timely project progress and increasing market share[192] Research and Development - The company is committed to its long-term vision of becoming an internationally recognized pharmaceutical brand by 2030[8] - The company has established a global research and development center for new drugs, emphasizing a high proportion of research and development investment to ensure continuous innovation[45] - The company has initiated over 20 early exploratory research projects in 2023, resulting in 14 authorized patents for innovative drugs[124] - The AI drug design platform has been established, enhancing drug development efficiency through deep integration of AI and CADD methods[126] - The company has submitted over 100 innovative drug patents in the past five years, with 10 patents authorized in 2024 alone[130] Acquisitions and Partnerships - The company fully acquired Hengba Pharmaceutical and established strategic partnerships with several domestic and international biopharmaceutical companies to enhance its innovative drug pipeline[6] - The company plans to acquire 100% equity of Guizhou Hengba Pharmaceutical Co., Ltd. for a base price of 528.47 million yuan[88] - The company signed an exclusive licensing agreement with IMBiologics for two global innovative products in the autoimmune field, IMB-101 and IMB-102, covering 37 Asian countries, including China[90] - The company entered into a strategic partnership with Shining Pharma to co-develop the siRNA candidate drug SNK-2726 for hypertension, obtaining exclusive rights for development, registration, production, and commercialization in Greater China[92] Corporate Social Responsibility and Sustainability - Huadong Medicine is committed to improving its ESG practices, aiming for a 10% reduction in carbon emissions by 2025[22] - The company achieved an MSCI ESG rating of A and a Shenzhen Stock Exchange ESG rating of AA, reflecting strong governance and sustainability practices[94] - The company has received multiple awards, including recognition in the "2024 China Private Enterprises 500" and "2024 Best Listed Company" by New Fortune magazine[95] Financial Investments and Cash Flow - The company has reported a total of 1.464 billion yuan in financial asset investments, focusing on securities investments[160] - The company’s total investment for the reporting period was ¥3.10 billion, representing a 29.97% increase from the previous year[154] - The company completed the acquisition of Guizhou Hengba Pharmaceutical Co., Ltd. for a total investment of 528.4 million yuan, holding 100% equity[155] - The company is actively pursuing market expansion through strategic acquisitions and investments in the pharmaceutical sector[155] Industry Trends and Market Outlook - The pharmaceutical industry is experiencing increased demand for innovative drugs and high-end medical devices due to aging population and health consumption upgrades[37] - The global pharmaceutical market is expected to reach $2.3 trillion by 2028, growing at an annual rate of 5-8%[174] - The medical aesthetics market in China is projected to grow at around 10% in 2024, driven by increasing consumer demand and market penetration[179] - By 2028, the oncology drug market is expected to reach $440 billion, with 100 new therapies anticipated to be introduced[174]

华东医药（000963）公告，2024年营业收入419.06亿元，同比增长3.16%。归属于上市公司股东的净利 润35.12亿元，同比增长23.72%。基本每股收益2元/股，同比增长23.60%。公司拟向全体股东每10股派 发现金红利5.8元(含税)，送红股0股(含税)，不以公积金转增股本。 ...

据了解，中证浙江企业综合指数与中证浙江民营企业指数分别选取注册地在浙江省的全部上市公司证券 与民营上市公司证券作为指数样本，以反映浙江省上市公司证券和民营上市公司证券的整体表现。该指 数以2004年12月31日为基日，以1000.0点为基点。 金融界4月14日消息，上证指数高开高走，中证浙江民营企业指数 (浙江民企，000840)报7165.72点。 数据统计显示，中证浙江民营企业指数近一个月下跌12.68%，近三个月上涨3.32%，年至今下跌 1.28%。 资料显示，指数样本每半年调整一次，样本调整实施时间分别为每年6月和12月的第二个星期五的下一 交易日。特殊情况下将对指数进行临时调整。当样本退市时，将其从指数样本中剔除。样本公司发生收 购、合并、分拆等情形的处理，参照计算与维护细则处理。 从指数持仓来看，中证浙江民营企业指数十大权重分别为：同花顺（2.27%）、三花智控（2.22%）、 华友钴业（1.69%）、恒生电子（1.58%）、拓普集团（1.32%）、华东医药（1.31%）、新和成 （1.3%）、大华股份（1.23%）、中控技术（1.22%）、卫星化学（1.15%）。 从中证浙江民营企业指数持仓样 ...

Group 1 - The Shanghai Composite Index opened high and the CSI 300 Pharmaceutical and Biotechnology Index reported 7370.94 points [1] - The CSI 300 Pharmaceutical and Biotechnology Index has decreased by 1.33% in the past month, increased by 5.20% in the past three months, and decreased by 0.98% year-to-date [1] - The CSI 300 Index is categorized into 11 primary industries, 35 secondary industries, over 90 tertiary industries, and more than 200 quaternary industries [1] Group 2 - The top ten weights in the CSI 300 Pharmaceutical and Biotechnology Index are: Heng Rui Medicine (24.17%), WuXi AppTec (14.58%), Pian Zai Huang (6.92%), Yunnan Baiyao (5.68%), Kelun Pharmaceutical (5.11%), East China Pharmaceutical (3.63%), New Hope Liuhe (3.58%), Shanghai Raas (3.57%), Changchun High-tech (3.53%), and Fosun Pharma (3.39%) [1] - The market share of the CSI 300 Pharmaceutical and Biotechnology Index is 61.98% from the Shanghai Stock Exchange and 38.02% from the Shenzhen Stock Exchange [2] - The industry composition of the index includes: chemical drugs (42.08%), traditional Chinese medicine (20.00%), pharmaceutical and biotechnology services (19.84%), and biological drugs (18.08%) [2] Group 3 - The index samples are adjusted every six months, with adjustments implemented on the next trading day after the second Friday of June and December each year [2] - Weight factors are generally fixed until the next scheduled adjustment, with temporary adjustments made when the CSI 300 Index samples are modified [2] - Special events affecting sample companies may lead to adjustments in the industry classification of the CSI 300 Industry Index [2]

丨2025年4月8日星期二丨 NO.1 北京：鼓励创新医药本地化生产 每经记者 许立波 每经编辑 马子卿 4月7日，北京市医疗保障局等九部门印发《北京市支持创新医药高质量发展若干措施（2025年）》。其 中提出，鼓励创新医药本地化生产。支持企业从国外引进重大药械品种，推动创新药械品种产业化落地 和规模化应用，承接医疗机构院内制剂配制和向创新药转化，"一企一策"做好服务。加强合同研发生产 组织平台建设，定期开展平台能力评价。 NO.2 深圳：对完成临床试验并实现海内外上市的1类创新药，给予最高3000万元资金奖励 4月7日，深圳市发改委等四部门印发《深圳市全链条支持医药和医疗器械发展若干措施》。措施提出， 全面支持医药研发和引进。聚焦核酸药物、蛋白和多肽药物、细胞药物、微生物药物、小分子创新药 物、现代中药等方向，支持引进或自主培育一批创新药成果。对完成临床试验并实现海内外上市的1类 创新药，面向其Ⅰ期、Ⅱ期、Ⅲ期临床试验研发环节，分别给予最高1000万元、2000万元、3000万元资 金奖励。大力支持宠物药发展，对获得一、二、三类新兽药注册证书的宠物药，分别给予300万元、200 万元、100万元奖励，单个企 ...

证券代码：000963 证券简称：华东医药 公告编号：2025-020 华东医药股份有限公司 注射用 DR30206 在中国的首个临床试验于 2023 年 6 月获得 NMPA 批准，适应症为晚期实体瘤（详见公司披露于巨潮资讯网的相 关公告，公告编号：2023-043）。 2025 年 1 月，道尔生物向 NMPA 递交了 DR30206 联合标准化疗 用于晚期或转移性消化道肿瘤患者的治疗的临床试验申请获得受理， 并于近日获得批准，同意本品开展临床试验。 三、对上市公司的影响及风险提示 截至目前，全球尚无同时靶向 PD-L1、VEGF 和 TGF-β 的抗体 融合蛋白药物上市，此次注射用 DR30206 联合标准化疗用于晚期或 转移性消化道肿瘤患者在中国的临床试验获批，是该款新药研发进程 中的又一大重要进展。 关于控股子公司获得药物临床试验批准通知书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 2025 年 4 月 3 日，华东医药股份有限公司（以下简称"公司"） 控股子公司浙江道尔生物科技有限公司（以下简称"道尔生物"）收到 国家药品监督管理局（N ...